Lead Product(s): Undisclosed
Therapeutic Area: Nephrology
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: DCVC Bio
Deal Size: $33.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 07, 2020
The financing will be used to advance the company’s lead hyperoxaluria program through Phase 1 clinical proof-of-concept work, as well as to expand its (GEMMs) platform.